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Abstract
Understanding challenges to virologic suppression is essential to optimizing health outcomes among individuals
with HIV. This cross-sectional behavioral assessment was conducted among 514 individuals presenting at an
urban U.S. HIV clinic between June and September 2007. The majority of the sample was African American and
male, with a mean age of 42 years. Most of the sample was receiving highly active antiretroviral therapy
(HAART), and the majority of those had suppressed viral loads (HIV viral loads less than 400 copies per
milliliter). By logistic regression analyses, African American=other minorities had 2.9 increased odds, those less
than high school degree had 2.3 increased odds, those who were receiving ritonavir-boosted protease inhibitor
therapy had 1.4 increased odds, and those who had expressed symptoms indicative of depressive disorders had
2.5 increased odds of having unsuppressed viremia as compared to Caucasians, those with more education,
receiving non-nucleoside reverse transcriptase inhibitor-based therapy, and who had minimal depressive
symptoms, respectively. These findings signify the importance of individualized interventions to enhance vi-
rologic suppression, both based on medication choices and individual characteristics.
Introduction
An estimated 56,000 new cases of HIV occur annually inthe United States.1 With the advances in antiretroviral
medications, HIV has been transformed into a manageable
chronic disease for those with access to treatment.2,3 Despite
these advances, AIDS-related deaths have remained stable
and patients too often present to care late in the course of their
HIV disease with an AIDS defining illness or immunologic
AIDS.1,2 Furthermore, there are continued disparities in the
management of individuals with HIV who are engaged in
medical care. Providers are often faced with significant chal-
lenges regarding retention, adherence to therapy, and man-
agement of comorbid illnesses such as psychiatric disorders
and substance abuse, particularly as HIV disproportionally
affects individuals of low socioeconomic status.
In efforts to improve medical care management, socio-
demographic characteristics and psychosocial stressors have
been examined as potential barriers to engagement and ad-
herence to medical care and treatment in the United States.4–8
Continued engagement in medical care is paramount to sur-
vival with HIV infection.9,10 As successful therapies have
become available, new challenges have arisen regarding ef-
fective timing and type of therapy for all patients. As newer
medications have been developed, the necessary adherence
threshold has fortunately declined.11,12 However, disparities
in the provision of care among lower income, African Amer-
icans, Latinos, and drug-using populations receiving highly
active antiretroviral therapy (HAART) remains prevalent.13,14
Specifically, women and African Americans with low annual
income and depressive symptoms have been reported to ad-
here to HAART less successfully, and may suggest a pre-
conceived bias in treatment choices by providers.7,8,15
HIV medical outcomes are affected by the complex lives
and environments in which individuals live. Publicly funded
infrastructures have been established to ensure access to
medical and ancillary care services for individuals with
HIV in the United States. These infrastructures attempt
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to overcome some of the substantial barriers to care and
treatment of HIV. In order to optimize health outcomes,
understanding the sociodemographic characteristics and
variations in treatment are necessary. This study was con-
ducted to increase understanding of some of the barriers,
both sociodemographics and treatment practices, to suc-
cessful management of HIV in a publicly-funded urban,
midwestern U.S. medical center.
Methods
This was a cross-sectional study of sociodemographic and
treatment factors, and their effect onHIV viral load. As part of
standard-of-care, all patients with HIV who attended the
Washington University HIV Clinic (WU HIV Clinic) in St.
Louis, Missouri, completed a behavioral assessment during
regular clinic visits, in which less than 3% (n¼ 15) of the clinic
population surveyed refused to complete the interview. These
assessments were conducted while individuals were waiting
to be seen by their health care providers. All patients who
presented in the clinic and had completed assessments be-
tween June and September 2007 were eligible to participate.
This studywas approved byWashingtonUniversity School of
Medicine Human Research Protection Office.
WU HIV Clinic is the major provider of HIV clinical care
and supportive services to people living with HIV=AIDS in
the St. Louis region. A comprehensive range of services is
available for HIV=AIDS patients served at WU HIV Clinic,
including: laboratory services, medical case management,
mental health care, patient education, peer treatment adher-
ence counseling, support groups, transportation, childcare,
and access to clinical trials research.
The behavioral assessment was conducted by a trained
interviewer with each patient as they waited for their pro-
vider. These assessments included measures of demographic
characteristics (race=ethnicity, employment, education, and
annual income), self-reportedmedication adherence using the
4-day AIDS Clinical Trial Group adherence instrument,16 and
depressive symptomatology as measured by the Patient
Health Questionnaire (PHQ-9).17 The PHQ-9 is used to cal-
culate severity and symptom counts that signify major de-
pressive disorder (MDD) and other depressive disorders
(ODD).18 Self-reported medication adherence was analyzed
using 95% adherence cutoff as calculated by the number of
pills prescribed the previous 4 days and the number reported
taken, which were then dichotomized at less than 95% and
greater than 95% to adhere to prescribed standards.18
Current CD4 cell count, plasma HIV RNA level, use and
types of prescribed antiretroviral therapies were collected at
time of the visit. HAART was defined as the use of at least
three drugs from two different antiretroviral drug classes,
Protease inhibitor (PI) or non-nucleoside reverse transcriptase
inhibitor (NNRTI), or the use of more than three nucleoside
reverse transcriptase inhibitors (NRTI). The number of the
regimen was collected and dichotomized to first line of ther-
apy or second line and greater. As it is expected that indi-
viduals who receive more than second lines of therapy have
increased difficulty managing their care, this was included to
assess any related factors in the analyses. Participants re-
ceiving HAART were categorized into NNRTI-based or PI-
based therapies. There were only five individuals receiving an
unboosted PI-based regimen. The participants receiving three
NRTIs (n¼ 10) were excluded from therapy-based analyses.
Additional analyses were conducted among individuals
having a CD4 cell count less than 350 cells=mm3 to examine
factors among individuals who, based on U.S. guidelines are
to be receiving HAART, and regardless of prescription con-
tinue to have low CD4 cell counts.17 Virologic suppression
was defined as having an HIV RNA level of less than 400
copies per milliliter. Previous work by our group has identi-
fied this threshold to be highly correlated with subsequent
virologic failure.19
Statistical analyses
Descriptive analyseswere conducted to describe the sample.
Bivariate analyses (t tests and analysis of variance [ANOVA])
were used to assess differences in the sample by gender and
HIV-related measures. Differences in gender were hypothe-
sized to exist based on previous research that found women
to be less adherent to medication.21 Tukey post hoc analyses
were used for pair-wise comparisons in conjunction with the
ANOVAs. Logistic regression analyses were conducted,
the final model was presented as the best fit using likelihood
ratios. Analyses related to virologic suppression were con-
ducted only with individuals who were on HAART (73%), as
it is expected that thosewith prescriptions have unsuppressed
viremia or do not currently meet recommended guidelines
for treatment.19 HIV viral loads were used as a proxy for
medication adherence. HIV viral loads were dichotomized
(less than 400 copies per milliliter and greater than 400 copies
per milliliter) to allow for binary logistic regression analyses
to be conducted in efforts to determine factors that serve as
predictors of effective virologic suppression (race, gender,
employment status, education level, depressive symptom-
atology). Education levels were dichotomized: less than high
school graduate=GED or more than a high school degree.
Employment status was dichotomized into unemployed (in-
cluding receiving disability benefits) and employed (part- or
full-time). Annual income was dichotomized into less than
and greater than $10,000. Depression severity was dichoto-
mized to those who expressed symptoms of major or other
depressive disorders (MDD=ODD) within the past 2 weeks
and those who did not. Age was categorized for regression
analyses (18–34, 35–49, older than 50 years). The 4-day recall
of medication adherence was dichotomized as less than
95% and more than 95% adherent. All tests were two-tailed
and p< 0.05 was considered significant. Data analyses were
performed using SPSS software (version 16.0; SPSS Inc.,
Chicago, IL).
Results
A total of 514 individuals completed the assessments be-
tween June and September 2007. The majority of the sample
was male (68%) and African American (59%), which is rep-
resentative of the clinic population. There were few non-
African American minorities (n¼ 46) and individuals who
reported their race as ‘‘other,’’ therefore race was dichoto-
mized into Caucasian versusAfricanAmericans= other racial=
ethnic minorities. The mean age of the clinic-based sample
was 41.8 years. A significant portion of the sample completed
a college or graduate degree (42%). A large proportion of the
sample reported an annual salary of less than $10,000 (47%),
while 16% reported more than $30,000. There were partici-
230 SHACHAM ET AL.
pants who refused to respond to annual income (n¼ 44).
Minimal data were missing among the employment status
(n¼ 1). Income was not used in the final analyses due to the
correlation with employment status among this population,
(Pearson’s r¼ 0.47; p< 0.001). Employment status rather than
income was used. Table 1 depicts additional sample details.
There were no gender differences regarding CD4 cell count or
strata, yetwomenwere receivingHAART less frequently than
men (65% versus 76%; p¼ 0.007). As such, women had higher
mean log10 HIV viral loads ( p¼ 0.02), with more women
having greater than 400 copies per milliliter (43% versus
27%; p¼ 0.003).
Subsequent analyses were conducted only among indi-
viduals receiving HAART. Almost three quarters (n¼ 370) of
the sample was receiving HAART at the time of the interview
and of those, 89% (n¼ 330) of the sample had a HIV viral load
of less than 400 copies per milliliter. Similar proportions of the
sample were receiving a PI-based therapy (48%) and NNRTI-
based therapy (49%), 10 patients were receiving other
HAART regimens. Only five respondents were receiving an
unboosted PI-based therapy. Among those on HAART, wo-
men ( p< 0.05), African American=other minorities ( p<
0.001), between the ages of 18 and 34 years ( p¼ 0.01), those
with less than a high school degree=GED ( p< 0.001), on PI-
based therapy ( p¼ 0.032), on at least their second line of
therapy ( p< 0.05), and with symptoms of depressive disor-
ders ( p¼ 0.004) were associated with viral load greater than
400 copies per milliliter.
One quarter of the sample reported less than 95% medi-
cation adherence using the ACTG 4-day medication recall.
Log10 HIV RNA level and self-reported adherence were
negatively correlated (Pearson’s r¼ 0.52, p< 0.001). African
American=other minority participants more often reported
less than 95% medication adherence (35% versus 15%;
p< 0.001) and had viral loads greater than 400 copies per
milliliter (15% versus 4%; p¼ 0.001) compared to Caucasian
participants. Lower education attainment was associated
with lower self-reported medication adherence as compared
to those with higher levels of education completed (33%
versus 23%; p< 0.05) and having a viral load greater than 400
copies per milliliter (17% versus 6%; p¼ 0.001). Employment
status and income were not significantly associated with self-
reported medication adherence or virologic suppression.
There were no differences in whowas receiving PI-based or
NNRTI-based therapies by gender, race, education attain-
ment, depressive symptoms, or homelessness. Individuals
with an annual income of less than $10,000 (58% versus 39%;
p< 0.001) and who were unemployed (67% versus 53%;
p¼ 0.008) more often were receiving PI-based HAART com-
pared to individuals with an annual income greater than
$10,000 and who were employed at least part-time, respec-
tively. Self-reported medication adherence less than 95%
occurred more frequently (34% versus 22%; p¼ 0.01) and
unsuppressed viral loads occurred more often among indi-
viduals prescribed PI-based therapy (15% versus 7%;
p¼ 0.009). Only one individual who was prescribed NNRTI-
based therapy had unsuppressed viremia (>400 copies per
milliliter).
About one third of the individuals with CD4 cell counts less
than 350 cells=mm3 (n¼ 64) were not currently prescribed
HAART. Individuals not on HAART more often were female
(46% versus 30%; p¼ 0.03), were African American=other
ethnic minorities (42% versus 17%; p¼ 0.003), had less than a
high school degree (43% versus 25%; p¼ 0.014), annual in-
come of less than $10,000 (44% versus 26%; p¼ 0.015), and had
MDD=ODD (41% versus 28%; p¼ 0.05) than their counter-
parts who had CD4 cell counts less than 350 cells=mm3 cell
counts and were on HAART. Additional details of these re-
lationships are depicted in Table 2.
Table 3 shows details of the relationships between socio-
demographic factors and clinic parameters. In unadjusted
logistic regression models, individuals who were female,
African American=other minorities, aged between 18 and 35
years, less than a high school degree=GED, had major or
other depression disorder symptoms (MDD=ODD), were
receiving PI-based therapy, and more than first regimen of
HAART were more likely to have had a viral load greater
than 400 copies per milliliter (each p< 0.05). After adjusting
for gender, age, employment status, and type of therapy (PI-
or NNRTI-based), individuals who were African Ameri-
can=other minorities had 2.85 greater odds of having un-
suppressed viral loads than their Caucasian counterparts,
those who completed less education had 2.32 greater odds of
having unsuppressed viral loads as compared to those with
higher levels of education, those who were receiving PI-
based therapy had 1.40 greater odds to have unsuppressed
viral loads than those on NNRTI-based therapy, and those
who had expressed symptoms indicative of MDD=ODD had
2.53 greater odds of having unsuppressed viral loads unlike
those who had minimal depressive symptoms.












18–34 years 141 27.9
35–49 years 253 50.0







>High school 260 50.6
High school diploma 254 49.4
Annual income (n¼ 471)
> $10,000 231 44.9
< $10,000 239 46.5
Consider self homeless 39 7.6
Depressive disorders (n¼ 503)
No disorders 283 55.1
MDD=ODD 220 42.8
Current HAART Prescription 370 72.0
MDD=ODD, major depressive disorder=other depressive disorders.
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Discussion
This sample was a demographically and clinically repre-
sentative sample of the overall population served at this
urban HIV clinic, which is similar to the current HIV epide-
miologic patterns of publicly funded clinics in the United
States.21 For the overwhelming majority of this clinic sample,
virologic suppression was achieved. This treatment success
was at least partly driven by self-reported adherence which
was moderately correlated with virologic suppression in our
sample. Individuals who were male, Caucasian, completed
greater than a high school degree, and reported minimal de-
pressive symptomatology were more likely to have achieved
virologic suppression (<400 copies per milliliter). Individuals
on first-line HAART were also more likely to have achieved
viral suppression. Among individuals with CD4 cell counts
less than 350 cells per milliliter, there were disparities by
gender, race=ethnicity, education, income, and depressive
disorders in regards to receipt of HAART.
It is evident from our analyses that patients at our clinic
who continue to receive medical care and adhere to their
treatment are more likely to successfully manage their HIV
disease compared with patients who are not adherent to their
prescribed treatment. While public infrastructures exist to
create supportive services for provision of care, some indi-
viduals are unable to overcome the complexities of their lives
in which HIV is just one part. The challenges that poverty
presents continue to impact health outcomes. Many socio-
demographic factors contribute to negative outcomes with
HIV treatments, including gender, race, income, timing
and type of therapy received.5,23–26 Women and African
Americans tend to have more challenges associated with en-
gagement in HIV care, experience difficulty adhering to
medication and higher rates of major depressive disorder,
lower annual income, and serostatus disclosure challenges
that tend to limit adherence.14,26–36 The relationship between
African American race and adherence-related virologic out-
comes may be mediated by certain demographic factors such
as low income, education attainment, and rates of employ-
ment that negatively affect medication adherence.26,27 Ad-
ditionally, reduced adherence may reflect concern for drug
toxicity rather than loss of efficacy.37 Prevalent depressive
disorders also negatively impacted virologic suppression.
While this finding is not novel, it illustrates the effect that co-
morbid conditions have on HIV disease, particularly psychi-
atric disorders, including substance use, depression, and
anxiety disorders.25,31–34 This finding highlights the impor-
tance of consistent screening of depressive symptoms and
treatment of psychiatric disorders. Additionally, many indi-
viduals have limited experience in symptom expression,
which may be additionally challenging in the context of their
HIV infection. Without active screening, there is likely to be a
relatively low level of symptom expression.32,36–39
Delays in HAART initiation are evident throughout pop-
ulations with HIV and are partially attributable to late diag-
nosis and entry into medical care among women and
racial=ethnic minorities; and thus more advanced disease
progression.5,14,33 Additionally, adherence to therapies tend
to decline over time, higher rates of failure have been shown
to occur with limited adherence to NNRTI-based therapy.5,6
Table 2. Comparisons among Individuals with CD4 Cell Counts
Less than 350 cells=mm3 (n¼ 184)
Not Currently on HAART (n¼ 64) Currently on HAART (n¼ 120)
n % n % p Value
Gender
Male 37 29.6 88 70.4 0.032
Female 27 45.8 32 54.2
Race
African American and other minorities 56 40.6 82 59.4 0.004
Caucasian 8 17.4 38 82.6
Age Category
18–34 years 22 43.1 29 56.9 0.226
35–49 years 34 33.7 67 63.3
 50 years 8 25.0 24 75.0
Employment status
Employed 22 34.4 42 65.6 0.932
Unemployed 42 35.0 78 65.0
Education
High school degree 43 42.6 58 57.4 0.014
>High school 21 25.3 62 74.7
Income (n¼ 168)
 $10,000 42 44.2 53 55.8 0.015
> $10,000 19 26.0 54 74.0
Consider self homeless 9 52.9 8 47.1 0.25
Depressive disorder symptoms (n¼ 180)
No disorders 25 27.2 67 72.8 0.052
Depressive disorder symptoms 36 40.9 52 59.1
Viral load < 400 copies per milliliter 3 3.4 86 96.6 0.001
HAART, highly active antiretroviral therapy.
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Overall, women in this study had higher HIV viral loads and
received HAART less often than men. This finding may re-
flect a provider bias that women are less likely to achieve
complete virologic suppression due to challenges with ser-
ostatus disclosure that impacts their adherence, and overall
complex social situations. We previously reported similar
findings that almost 50% of the women from our clinic
populationwere not successfully suppressing their HIV viral
load on HAART.37 While there was no appreciable differ-
ence in CD4 cell counts by gender, these findings suggest
further longitudinal examination of prescribing patterns for
HAART and timing of initiation of HAART. When on
HAART, women were more likely to be receiving PI-based
rather than NNRTI-based HAART, yet those on NNRTI-
based therapy had higher rates of adherence and virologic
suppression. The gender differences that exist between
PI-based and NNRTI-based therapies are most often due to
concerns for potential pregnancy risk incumbent with efa-
virenz (NNRTI-based). In our study sample, there was equal
distribution of NNRTI- and PI-based therapy. Additionally,
PI-based therapy may be necessary for patients who have
had difficulty adhering to medication, or are on second-line
therapy or greater due to antiretroviral resistance.45,46
Therefore, choices of the therapy type are often limited.
There were several limitations to our study. It was cross-
sectional in nature, and cannot determinewhether continued
adherence to HAART is associated with sustained viral
suppression and conducted in one publicly-funded Mid-
western urban clinic and therefore our results may not be
generalizable to other HIV patient populations. The inherent
bias in self-reported data is continually a challenge when
assessing risk behavior among individuals with HIV, yet
short recall instruments were selected to limit this bias.
Additionally, it has been documented that adherence rates
decline after a 30-month follow-up period, the cross sec-
tional nature of this study limits adding to this body of
knowledge.46
Our study highlights that treatment success continues to
be associated with sociodemographic factors including race,
income, education level, and gender. Race tends to be a
product of a complex network of factors that include socio-
economic status, education, and access to health care, which
may limit continued engagement in care and medication, or
overall social capital.44 In our clinic, much of the patient
population has a low annual income and struggles with other
survival challenges that are not specifically related to HIV.
Key features that have been highlighted in other research
include missed clinic visits,45 having children to care for in
Table 3. Sociodemographic Relationships with HIV Viral Load of Sample on HAART










n % n % n % p value confidence interval) confidence interval)
Gender
Male 263 71.1 240 91.3 23 8.7 0.045 Ref
Female 107 28.9 90 84.1 17 15.9 1.97 (1.01–3.86)
Race
Caucasian 134 36.2 129 96.3 5 3.7 0.001 Ref Ref
African American
and other minorities
236 63.8 201 85.2 35 14.8 4.50 (1.72–11.77) 2.85 (1.05–7.75)
Age Category
18–34 years 82 22.2 66 80.5 16 19.5* 0.01
35–49 years 192 51.9 174 90.7 18 9.4
 50 years 96 25.9 90 93.8 6 6.3*
Employment status (n¼ 369)
Employed 147 39.8 136 92.5 11 7.5 0.091 Ref
Unemployed=disability
benefits
222 60.2 193 86.9 29 13.0 1.85 (1.11–3.85)
Education level
>High school 203 54.9 191 94.1 12 5.9 0.001 Ref Ref
High school diploma 167 45.1 139 83.2 28 16.8 3.23 (1.58, 6.58) 2.32 (1.08–5.00)
Consider self homeless (n¼ 39) 20 23.3 15 75.0 5 25.0 0.159 2.42 (1.45, 8.46)
Depressive disorders (n¼ 364)
No disorders 210 57.7 196 93.3 14 6.6 0.002 Ref Ref
MDD=ODD 154 42.3 130 83.8 26 16.7 2.81 (1.42, 5.59) 2.53 (1.24–5.18)
HAART type (n¼ 360)
Ritonavir-boosted PI 178 48.1 151 84.8 27 15.2 0.009 Ref Ref
NNRTI-based 182 49.2 170 93.4 12 6.6 2.53 (1.24, 5.18) 1.40(1.03–1.92)
Drug regimen (n¼ 366)
1st line 236 64.5 217 91.9 19 8.1 0.017 Ref
2nd line 130 35.5 109 83.8 21 16.2 2.20 (1.14, 4.27)
aIdentifies differences between youngest and oldest category.
HAART, highly active antiretroviral therapy; MDD=ODD, PI, protease inhibitor; NNRTI, non¼nucleoside reverse transcriptase inhibitor
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the home (although not significant in this study),29,47 and
substance use disorders.10 The treatment and care of indi-
viduals with HIV continue to be complicated by sociodemo-
graphic factors that are not easily modified, and findings
suggest a need for further research regarding care provision is
warranted.
This study examined factors that are associated with suc-
cessful outcomes for individuals with HIV who are engaged
in medical care. Race, education attainment, and type of HIV
therapy play an essential role in determining HIV-related
health outcomes. These findings signify the importance of
individualized interventions to be delivered within HIV
testing and systems of care that address the disparities in HIV
care that exist, which have the potential to enhance engage-
ment into medical care and medication adherence, as well as
improve secondary prevention efforts.
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